Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 4/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.45 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 3/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843567 | 0.93 | KDR (0.48) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3842668 | 0.89 | KDR (0.59) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3847595 | 0.89 | KDR (0.46) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3850840 | 0.86 | LCK (0.57) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3844714 | 0.82 | KDR (0.46) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3852679 | 0.81 | KDR (0.47) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3847135 | 0.81 | KIT (0.57) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3851759 | 0.81 | KDR (0.43) | KDRNTRK2PDGFRBRETNTRK1 | |
| SCHEMBL3842705 | 0.80 | KDR (0.44) | KDRNTRK2RETNTRK1AURKB | |
| SCHEMBL13873225 | 0.80 | CSF1R (0.53) | KDRNTRK2PDGFRBRETNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125808-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-02 | — | — | EP | claimed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | claimed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | claimed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-1932845-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | claimed |
| EP-2125808-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1932845-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1932845-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | KDR 1/4885NTRK2 963/4885PDGFRB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.